Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical Inc. (Nasdaq: COLL) specializes in developing abuse-deterrent medications for chronic pain and neuropsychiatric conditions through its proprietary DETERx® technology. This news hub provides investors and healthcare professionals with timely updates on regulatory milestones, product developments, and strategic initiatives shaping the company's trajectory in specialty pharmaceuticals.
Access comprehensive coverage of COLL's latest press releases, including advancements in pain management solutions like Xtampza ER® and Nucynta®, as well as its expansion into ADHD treatment with Jornay PM®. The page aggregates essential updates on financial performance, partnership announcements, and intellectual property developments critical for assessing the company's market position.
Bookmark this resource for structured access to Collegium's most significant announcements, from clinical trial results to manufacturing updates. Our curated news feed ensures you stay informed about COLL's efforts to address opioid misuse while delivering innovative therapeutic solutions across multiple medical disciplines.
Collegium Pharmaceutical (Nasdaq: COLL) will host a conference call on May 10, 2022, at 4:30 p.m. ET, to discuss its Q1 2022 financial results and provide a corporate update. Interested parties can join by dialing (877) 407-8037 for U.S. callers or (201) 689-8037 for international callers. The call will also be available via a live audio webcast on the company’s website, with replays accessible two hours after the event.
Collegium is dedicated to enhancing the lives of those with serious medical conditions, headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical (Nasdaq: COLL) announced its participation in the 21st Annual Needham Virtual Healthcare Conference, set for April 13, 2022. Management will engage in a virtual fireside chat, which will be webcast and accessible through the investor section of the company's website. A replay will be available for 30 days following the event. Collegium is dedicated to enhancing the lives of those with serious medical conditions, headquartered in Stoughton, Massachusetts. For more details, visit www.collegiumpharma.com.
Collegium Pharmaceutical (Nasdaq: COLL) announced the appointment of Neil F. McFarlane to its Board of Directors, effective April 6, 2022. McFarlane brings extensive experience from previous leadership roles at Adamas Pharmaceuticals and Retrophin. The Chairman, Mike Heffernan, expressed confidence in McFarlane's ability to provide valuable insights and contributions. This strategic addition comes as the company aims to enhance its operations and improve the lives of individuals with serious medical conditions.
Collegium Pharmaceutical (Nasdaq: COLL) has updated its financial guidance for 2022 following the acquisition of BioDelivery Sciences International on March 22, 2022. Expected total product revenues are projected between $450.0 million and $465.0 million, reflecting a 65% increase from $276.9 million in 2021. Adjusted operating expenses are estimated at $130.0 million to $140.0 million and adjusted EBITDA is expected to reach $235.0 million to $250.0 million. The company aims for operational synergies of at least $75 million as it integrates BDSI.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has reached a Master Settlement Agreement to resolve 27 opioid-related lawsuits without admitting liability. Executed on March 18, 2022, the company has paid $2.75 million to the plaintiffs, leading to case dismissals anticipated in the upcoming weeks. This settlement follows a previously announced framework from December 2021, marking a strategic decision to mitigate legal risks. Collegium aims to strengthen its position as a specialty pharmaceutical company focused on aiding patients with serious medical conditions.
Collegium Pharmaceutical (Nasdaq: COLL) has completed its acquisition of BioDelivery Sciences International (Nasdaq: BDSI) for $5.60 per share, totaling approximately $40 million. This strategic move aims to enhance Collegium's revenue through diversification, adding products like BELBUCA and ELYXYB to its portfolio. The acquisition is expected to yield annual synergies of at least $75 million within the first year, strengthening Collegium's financial position and accelerating cash flow generation, while expanding its footprint in the neurology market.
Collegium Pharmaceutical (Nasdaq: COLL) reported its Q4 and full-year 2021 financial results, revealing a net loss of $25 million for Q4 and $71.5 million net income for the full year. The company anticipates 2022 revenues between $315 million and $330 million, driven by growth in Xtampza ER. They expect the BDSI acquisition to close in late Q1 2022, aiming for synergies exceeding $75 million. Despite challenges, Collegium ended 2021 with a cash balance of $186.4 million and achieved significant market share gains in Xtampza ER, with a 33% share of the oxycodone extended-release market.
Collegium Pharmaceutical (Nasdaq: COLL) announced an agreement to acquire BioDelivery Sciences International (BDSI) for $5.60 per share in cash, valuing BDSI at approximately $604 million. This acquisition, expected to close in Q1 2022, aims to enhance Collegium's portfolio in pain management and neurology, with estimated annual synergies of at least $75 million within 12 months. The transaction is anticipated to be accretive to earnings in 2022 and 2023, diversifying revenue sources and accelerating cash flow generation.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a conference call on February 24, 2022, at 4:30 p.m. ET to discuss its Q4 and full-year 2021 financial results. The call will be accessible via phone at (877) 407-8037 (U.S.) or (201) 689-8037 (International) and will also be available as a live audio webcast on their website. A replay will be posted approximately two hours after the event. Collegium is committed to advancing specialty pharmaceuticals aimed at improving patients' lives.
Collegium Pharmaceutical (Nasdaq: COLL) has reached a settlement framework to resolve 27 opioid-related lawsuits for a maximum payment of $2,750,000. This agreement aims to dismiss all pending cases while ensuring no admission of liability. The settlement, which awaits final approval, reflects the company's commitment to responsible pain management. Executive VP Shirley Kuhlmann expressed satisfaction with the resolution, indicating a focus on future operations free from this litigation burden.
